Mme Chair;

It is important that the Director General urgently work with the Global Influenza Surveillance and Response System and other partners to address uncertainties related to sharing of seasonal influenza viruses that have emerged as countries implement the Nagoya Protocol. It is equally important to address implications for use of shared viruses and genetic data for vaccine production.

Norway supports the amendments to the draft decision presented by the EU.

We have one question about the draft decision;

- What is the rationale behind correcting the SMTA 2 loophole at this time? Could you give an example of what this amendment seeks to address?

Thank you.